Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer

Human Cell

Volumn 22, Issue 4, 2009, Pages 101-106

  Nunobiki, Osamu ^a   Ueda, Masatsugu ^b   Yamamoto, Michiko ^b   Toji, Eisaku ^b   Sato, Naomi ^c   Izuma, Shinji ^b   Okamoto, Yoshiaki ^b   Torii, Kiyo ^b   Noda, Sadamu ^b  

^a KOBE TOKIWA UNIVERSITY   (Japan)

^b Osaka Cancer Prevention and Detection Center   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Endometrial cancer; MDM2 SNP309; P53 codon 72; Polymorphism

Indexed keywords

ARGININE; DNA; PROTEIN MDM2; PROTEIN P53;

ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; CODON; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, P53; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RISK;

MURINAE;

EID: 70350510097     PISSN: 09147470     EISSN: 17490774     Source Type: Journal    
DOI: 10.1111/j.1749-0774.2009.00075.x     Document Type: Article

References (25)

1. Tsigris C, Chatzitheofylaktou A, Xiromeritis C et al. Genetic association studies in digestive system malignancies. Anticancer Res 2007 27 : 3577 3587.
2. Ueda M, Hung YC, Terai Y et al. Glutathione S-transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells. Hum Cell 2003 16 : 241 251.
3. Ueda M, Toji E, Nunobiki O et al. Germline polymorphism of cancer susceptibility genes in gynecologic cancer. Hum Cell 2008 21 : 95 104.
4. Dulic V, Kaufmann WK, Wilson SJ et al. p53 dependent inhibition of cyclin-dependent kinase activities in human fibroblast during radiation-induced G1 arrest. Cell 1994 76 : 1013 1023.
5. Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res 2001 264 : 56 66.
6. Greenblatt MS, Bennett WP, Hollstein M et al. Mutations in the p53 gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994 55 : 4855 4878.
7. Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 1990 18 : 4961.
8. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997 387 : 299 303.
9. Bond GL, Hu W, Bond EE et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004 119 : 591 602.
10. Menin C, Scaini MC, De Salvo GL et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006 98 : 285 288.
11. Dharel N, Kato N, Muroyama R et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 2006 12 : 4867 4871.
12. Lum SS, Chua HW, Li H et al. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 2008 29 : 754 761.
13. Buchynska LG, Nesina IP, Kashuba EV. Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia. Exp Oncol 2007 29 : 287 294.
14. Horrée N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP. Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J Clin Pathol 2008 61 : 36 42.
15. Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 2007 104 : 660 664.
16. Terry K, McGrath M, Lee IM, Buring J, De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2008 17 : 983 986.
17. Ueda M, Gemmill RM, West J et al. Mutations of the β- and γ-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer 2001 85 : 64 8.
18. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987 7 : 961 963.
19. Roh JW, Kim JW, Park NH et al. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol 2004 93 : 499 505.
20. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer 1997 75 : 1385 1388.
21. Peller S, Halperin R, Schneider D, Kopilova Y, Rotter V. Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol Rep 1999 6 : 193 197.
22. Agorastos T, Masouridou S, Lambropoulos AF et al. P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev 2004 13 : 277 280.
23. Ashton KA, Proietto A, Otton G et al. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol 2009 113 : 109 114.
24. Boersma BJ, Howe TM, Goodman JE et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 2006 98 : 911 919.
25. Schmidt MK, Reincke S, Broeks A et al. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 2007 67 : 9584 9590.